So far this season, the CDC estimates that there have been at least 24 million flu-related illnesses, 310,000 hospitalizations, and 20,000 deaths.
The latest FDA reversal is welcome, but the episode of first denying Moderna review of its mRNA flu vaccine deserves close examination.
Between federal lawsuits, sweeping schedule changes, and states mobilizing their own legal challenges, the last few weeks have been a whirlwind. Let's dive right in.
But the spray won’t replace flu vaccination because it stays in the nose for only a few hours.
The FDA had refused to review the original application because it said Moderna’s phase 3 study was not "adequate and well-controlled."
Trial aims to study the safety and immunogenicity of the vaccine in healthy adults aged 18 to 64 years or 65 and older.
The company expressed surprise and confusion about the decision, noting the FDA’s earlier support for the study plan.
The perceived safety of the MMR vaccine is now 83% (down from 86%).
The findings of the meta-analysis draw on data from more than 23 million people.
The vaccine is 40% against medically attended infection with influenza A(H3N2) viruses, 37% against subclade K of the H3N2 strain, and 31% against H1N1 influenza A.
